{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:02:31Z","timestamp":1789923751964,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s10620-016-4334-8","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T07:59:04Z","timestamp":1476259144000},"page":"3395-3404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["FXR Agonists: From Bench to Bedside, a Guide for Clinicians"],"prefix":"10.1007","volume":"61","author":[{"given":"Ahmad Samer","family":"Alawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,12]]},"reference":[{"key":"4334_CR1","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1101\/gad.12.20.3149","volume":"12","author":"B Blumberg","year":"1998","unstructured":"Blumberg B, Evans RM. Orphan nuclear receptors\u2013new ligands and new possibilities. Genes Dev. 1998;12:3149\u20133155.","journal-title":"Genes Dev"},{"key":"4334_CR2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731\u2013744.","journal-title":"Cell"},{"key":"4334_CR3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147\u2013191.","journal-title":"Physiol Rev"},{"key":"4334_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217\u2013225.","journal-title":"Cell Metab"},{"key":"4334_CR5","doi-asserted-by":"crossref","first-page":"41930","DOI":"10.1074\/jbc.M306309200","volume":"278","author":"T Kok","year":"2003","unstructured":"Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem. 2003;278:41930\u201341937.","journal-title":"J Biol Chem"},{"key":"4334_CR6","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362\u20131365.","journal-title":"Science"},{"key":"4334_CR7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tips.2007.03.002","volume":"28","author":"B Cariou","year":"2007","unstructured":"Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci. 2007;28:236\u2013243.","journal-title":"Trends Pharmacol Sci"},{"key":"4334_CR8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","volume":"17","author":"JA Holt","year":"2003","unstructured":"Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581\u20131591.","journal-title":"Genes Dev"},{"key":"4334_CR9","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632\u20131643.","journal-title":"Hepatology"},{"key":"4334_CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","volume":"53","author":"M Wagner","year":"2011","unstructured":"Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023\u20131034.","journal-title":"Hepatology"},{"key":"4334_CR11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","volume":"17","author":"L Adorini","year":"2012","unstructured":"Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988\u2013997.","journal-title":"Drug Discov Today"},{"key":"4334_CR12","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","volume":"47","author":"R Pellicciari","year":"2004","unstructured":"Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47:4559\u20134569.","journal-title":"J Med Chem"},{"key":"4334_CR13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","volume":"51","author":"S Cipriani","year":"2010","unstructured":"Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats. J Lipid Res. 2010;51:771\u2013784.","journal-title":"J Lipid Res"},{"key":"4334_CR14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1743-6109.2010.02073.x","volume":"8","author":"L Vignozzi","year":"2011","unstructured":"Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med. 2011;8:57\u201377.","journal-title":"J Sex Med"},{"key":"4334_CR15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","volume":"103","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006\u20131011.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4334_CR16","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","volume":"281","author":"B Cariou","year":"2006","unstructured":"Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039\u201311049.","journal-title":"J Biol Chem"},{"key":"4334_CR17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","volume":"30","author":"Y Ma","year":"2013","unstructured":"Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res. 2013;30:1447\u20131457.","journal-title":"Pharm Res"},{"key":"4334_CR18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621\u20131624.","journal-title":"Science"},{"key":"4334_CR19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","volume":"61","author":"E Seki","year":"2015","unstructured":"Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015;61:1066\u20131079.","journal-title":"Hepatology"},{"key":"4334_CR20","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"SL Friedman","year":"2003","unstructured":"Friedman SL. Liver fibrosis\u2014from bench to bedside. J Hepatol. 2003;38:S38\u2013S53.","journal-title":"J Hepatol"},{"key":"4334_CR21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497\u20131512.","journal-title":"Gastroenterology"},{"key":"4334_CR22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","volume":"28","author":"I Kim","year":"2007","unstructured":"Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28:940\u2013946.","journal-title":"Carcinogenesis"},{"key":"4334_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hep.27274","volume":"61","author":"C Degirolamo","year":"2015","unstructured":"Degirolamo C, Modica S, Vacca M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015;61:161\u2013170.","journal-title":"Hepatology"},{"key":"4334_CR24","doi-asserted-by":"crossref","first-page":"34606","DOI":"10.18632\/oncotarget.5314","volume":"6","author":"F Guo","year":"2015","unstructured":"Guo F, Xu Z, Zhang Y, et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget. 2015;6:34606\u201334616.","journal-title":"Oncotarget"},{"key":"4334_CR25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12943-015-0427-9","volume":"14","author":"J He","year":"2015","unstructured":"He J, Zhao K, Zheng L, et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer. 2015;14:163.","journal-title":"Mol Cancer"},{"key":"4334_CR26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/jm8014124","volume":"52","author":"B Flatt","year":"2009","unstructured":"Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904\u2013907.","journal-title":"J Med Chem"},{"key":"4334_CR27","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","volume":"296","author":"A Mencarelli","year":"2009","unstructured":"Mencarelli A, Renga B, Distrutti E, et al. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296:H272\u2013H281.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4334_CR28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","volume":"443","author":"W Wu","year":"2014","unstructured":"Wu W, Zhu B, Peng X, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014;443:68\u201373.","journal-title":"Biochem Biophys Res Commun"},{"key":"4334_CR29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cbi.2014.03.014","volume":"217","author":"FA Livero","year":"2014","unstructured":"Livero FA, Stolf AM, Dreifuss AA, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact. 2014;217:19\u201327.","journal-title":"Chem Biol Interact"},{"key":"4334_CR30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2014.04.048","volume":"448","author":"W Wu","year":"2014","unstructured":"Wu W, Liu X, Peng X, et al. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2014;448:50\u201355.","journal-title":"Biochem Biophys Res Commun"},{"key":"4334_CR31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","volume":"51","author":"S Zhang","year":"2009","unstructured":"Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380\u2013388.","journal-title":"J Hepatol"},{"key":"4334_CR32","doi-asserted-by":"crossref","first-page":"14430","DOI":"10.3748\/wjg.v20.i39.14430","volume":"20","author":"J Yao","year":"2014","unstructured":"Yao J, et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20:14430\u201314441.","journal-title":"World J Gastroenterol"},{"key":"4334_CR33","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Zhou CS, Ma X, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569\u20133572.","journal-title":"J Med Chem"},{"key":"4334_CR34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.placenta.2015.02.005","volume":"36","author":"WB Wu","year":"2015","unstructured":"Wu WB, Xu YY, Cheng WW, et al. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta\u2014a study on maternal cholestasis model. Placenta. 2015;36:545\u2013551.","journal-title":"Placenta"},{"key":"4334_CR35","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3892\/mmr.2015.4159","volume":"12","author":"F Lian","year":"2015","unstructured":"Lian F, Wang Y, Xiao Y, et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. Mol Med Rep. 2015;12:5821\u20135827.","journal-title":"Mol Med Rep"},{"key":"4334_CR36","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","volume":"183","author":"A Mencarelli","year":"2009","unstructured":"Mencarelli A, Renga B, Migliorati M, et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol. 2009;183:6657\u20136666.","journal-title":"J Immunol"},{"key":"4334_CR37","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286\u20132298.","journal-title":"Hepatology"},{"key":"4334_CR38","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nm1138","volume":"10","author":"A Moschetta","year":"2004","unstructured":"Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10:1352\u20131358.","journal-title":"Nat Med"},{"key":"4334_CR39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387\u20131395.","journal-title":"Hepatology"},{"key":"4334_CR40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","volume":"50","author":"G Marchesini","year":"2001","unstructured":"Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844\u20131850.","journal-title":"Diabetes"},{"key":"4334_CR41","doi-asserted-by":"crossref","first-page":"574-82.e1","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1.","journal-title":"Gastroenterology"},{"key":"4334_CR42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u2013965.","journal-title":"Lancet"},{"key":"4334_CR43","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/S0168-8278(15)30169-0","volume":"62","author":"B Hameed","year":"2015","unstructured":"Hameed B, Terrault N, Gill R, et al. Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH). J Hepatol. 2015;62:S271.","journal-title":"J Hepatol"},{"key":"4334_CR44","doi-asserted-by":"crossref","first-page":"751-61.e8","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-61.e8.","journal-title":"Gastroenterology"},{"key":"4334_CR45","volume-title":"An International Study Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid as Monotherapy in PBC","author":"KV Kowdley","year":"2011","unstructured":"Kowdley KV, Luketic V, Chapman R. An International Study Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid as Monotherapy in PBC. Vol. 54. Berlin: European Association for the Study of the Liver; 2011."},{"key":"4334_CR46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631\u2013643.","journal-title":"N Engl J Med"},{"key":"4334_CR47","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/jbmr.1961","volume":"28","author":"SW Cho","year":"2013","unstructured":"Cho SW, An JH, Park H, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28:2109\u20132121.","journal-title":"J Bone Miner Res"},{"key":"4334_CR48","doi-asserted-by":"crossref","first-page":"S786","DOI":"10.1016\/S0168-8278(15)31352-0","volume":"62","author":"A Pares","year":"2015","unstructured":"Pares A, Pencek R, Peters Y, et al. FXR agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. J Hepatol. 2015;62:S786.","journal-title":"J Hepatol"},{"key":"4334_CR49","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60017-9","volume":"60","author":"R Mookerjee","year":"2014","unstructured":"Mookerjee R, Rosselli M, Pieri G, et al. Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2 a study. J Hepatol. 2014;60:S7-S8.","journal-title":"J Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-016-4334-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T04:34:48Z","timestamp":1657427688000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-016-4334-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1007\/s10620-016-4334-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,12]]}}}